Establishing a parallel compound screening method and identifying novel antimicrobial compounds targeting Staphylococcus aureus dihydrofolate reductase

Junpei Nakashima Masamune Takeuchi Shuhei Kawamoto Kohei Monobe Junichi Taira Shunsuke Aoki   

Open Access   

Published:  Jun 20, 2022


The emergence of drug-resistant Staphylococcus aureus strains, such as methicillin-resistant S. aureus and vancomycinresistant S. aureus, and their spread not only inside hospitals but also outside hospitals has become a major problem worldwide. In this study, we investigated novel antimicrobial compounds targeting trimethoprim-resistant S. aureus dihydrofolate reductase (TMP-resistant saDHFR). A novel screening method, called the parallel compound screening (PCS) method, was established to analyze a common population of compounds that showed top scores using two docking tools, GOLD and AutoDock Vina. Using 154,118 compounds in the structural library, we conducted a threestep in silico structure-based drug screening, including PCS, and identified nine candidate compounds targeting TMP-resistant saDHFR. The growth inhibitory effects of the candidate compounds on bacteria were examined on Staphylococcus epidermidis, a model microbial strain of S. aureus. Among the candidate compounds, two compounds showed strong growth inhibition against S. epidermidis. The IC50 values of the two compounds (6.34 and 56.94 µM) were determined. Molecular dynamics simulations predicted the direct and stable interactions between the active compounds and TMP-resistant saDHFR. The data regarding these active compounds from this study are expected to contribute to the development of new antibacterial agents against drug-resistant strains of S. aureus.

Keyword:     DHFR Staphylococcus aureus antibiotics structurebased drug screening parallel compound screening molecular dynamics.


Nakashima J, Takeuchi M, Kawamoto S, Monobe K, Taira J, Aoki S. Establishing a parallel compound screening method and identifying novel antimicrobial compounds targeting Staphylococcus aureus dihydrofolate reductase. J Appl Pharm Sci,2022. Online First.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


Ahmed MF, Santali EY, El-Haggar R. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. J Enzyme Inhib Med Chem, 2021; 36:307-18.

Gentile F, Agrawal V, Hsing M, Ton A-T, Ban F, Norinder U, Gleave ME, Cherkasov A. Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent Sci, 2020; 6:939-49.

Guterres H, Im W. Improving protein-ligand docking results with high-throughput molecular dynamics simulations. J Chem Inf Model, 2020; 60:2189-98.

He J, Qiao W, An Q, Yang T, Luo Y. Dihydrofolate reductase inhibitors for use as antimicrobial agents. Eur J Med Chem, 2020; 195.

Holland TL, Arnold C, Fowler VG. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA, 2014; 312:1330-41.

Huang DB, Noviello S, Balser B, Scaramucci A, Corey GR. A Pooled analysis of the safety and efficacy of iclaprim versus vancomycin for the treatment of acute bacterial skin and skin structure infections in patients with intravenous drug use: phase 3 REVIVE studies. Clin Ther, 2019; 41:1090-6.

Keshipeddy S, Reeve SM, Anderson AC, Wright DL. Nonracemic antifolates stereoselectively recruit alternate cofactors and overcome resistance in S. aureus. J Am Chem Soc, 2015; 137:8983-90.

Khan A, Wilson B, Gould IM. Current and future treatment options for community-associated MRSA infection. Expert Opin Pharmacother, 2018; 19:457-70.

Kinjo T, Koseki Y, Kobayashi M, Yamada A, Morita K, Yamaguchi K, Tsurusawa R, Gulten G, Komatsu H, Sakamoto H, Sacchettini JC, Kitamura M, Aoki S. Identification of compounds with potential antibacterial activity against Mycobacterium through structurebased drug screening. J Chem Inf Model, 2013; 53:1200-12.

Kobayashi M, Kinjo T, Koseki Y, Bourne CR, Barrow WW, Aoki S. Identification of novel potential antibiotics against Staphylococcus using structure-based drug screening targeting dihydrofolate reductase. J Chem Inf Model, 2014; 54:1242-53.

Kuriki K, Taira J, Kuroki M, Sakamoto H, Aoki S. Computerassisted screening of mycobacterial growth inhibitors: Exclusion of frequent hitters with the assistance of the multiple target screening method. Int J Mycobacteriol, 2021; 10:307-11.

Labute P. LowModeMD-implicit low-mode velocity filtering applied to conformational search of macrocycles and protein loops. J Chem Inf Model, 2010; 50:792-800.

Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev, 2018; 31.

Li X, Hilgers M, Cunningham M, Chen Z, Trzoss M, Zhang J, Kohnen L, Lam T, Creighton C, G C K, Nelson K, Kwan B, Stidham M, Brown-Driver V, Shaw KJ, Finn J. Structure-based design of new DHFRbased antibacterial agents: 7-aryl-2,4-diaminoquinazolines. Bioorg Med Chem Lett, 2011; 21:5171-6.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 2012; 64:4-17.

McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med, 2017; 90:269-81.

Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking. J Med Chem, 2012;55:6582-94.

Pereira JC, Caffarena ER, dos Santos CN. Boosting dockingbased virtual screening with deep learning. J Chem Inf Model, 2016; 56:2495-506.

Pinzi L, Rastelli G. Molecular docking: Shifting paradigms in drug discovery. Int J Mol Sci, 2019; 20.

Reddy KK, Rathore RS, Srujana P, Burri RR, Reddy CR, Sumakanth M, Reddanna P, Reddy MR. Performance evaluation of docking programs- glide, gold, autodock & surflexdock, using free energy perturbation reference data: a case study of fructose-1, 6-bisphosphataseAMP analogs. Mini Rev Med Chem, 2020; 20:1179-87.

Reeve SM, Si D, Krucinska J, Yan Y, Viswanathan K, Wang S, Holt GT, Holt GT, Ojewole AA, Estrada A, Agabiti SS, Alverson JB, Gibson ND, Priestley ND, Wiemer AJ, Donald BR, Wright DL. Toward broad spectrum dihydrofolate reductase inhibitors targeting trimethoprim resistant enzymes identified in clinical isolates of methicillin resistant Staphylococcus aureus. ACS Infect Dis, 2019; 5:1896-906.

Scarpino A, Ferenczy GG, Keser? GM. Comparative evaluation of covalent docking tools. J Chem Inf Model, 2018; 58:1441-58.

Sharma AK, Srivastava GN, Roy A, Sharma VK. ToxiM: a toxicity prediction tool for small molecules developed using machine learning and chemoinformatics approaches. Front Pharmacol, 2017; 8.

Taira J, Morita K, Kawashima S, Umei T, Baba H, Maruoka T, Komatsu H, Sakamoto H, Sacchettini JC, Aoki S. Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening. J Antibiot (Tokyo), 2017; 70:1057-64.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 2010; 31:455-61.

Uciechowska-Kaczmarzyk U, Chauvot de Beauchene I, Samsonov SA. Docking software performance in protein-glycosaminoglycan systems. J Mol Graph Model 2019; 90:42-50.

Wang C, Zhang Y. Improving scoring-docking-screening powers of protein-ligand scoring functions using random forest. J Comput Chem, 2017; 38:169-77.

Wang S, Reeve SM, Holt GT, Ojewole AA, Frenkel MS, Gainza P, Keshipeddy S, Fowler VG, Wright DL, Donald BR. Chiral evasion and stereospecific antifolate resistance in Staphylococcus aureus. PLoS Comput Biol, 2022; 18.

Wróbel A, Arciszewska K, Maliszewski D, Drozdowska D. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors. J Antibiot (Tokyo), 2020; 73:5-27.

Article Metrics

1 Absract views 0 PDF Downloads 1 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required